HN-02470278_Anti-Inflammation Effects of L-Carnitine Supplementation in Critical Ill Patients

Introduction: Critical ill patients in the intensive care unit, are usually associated with catabolic stress conditions, during which this situation show systemic inflammatory symptoms and responses. Inflammatory responses are associated with increased complications such as infectious diseases, multi-organ dysfunction. increased length of ICU stay and mortality. Critically ill patients are usually nourished artificially by enteral or parenteral feeding, which often leads to a lack of L-Carnitine intake. L-Carnitine supplementation may play an important role in these patients by regulating inflammatory cell function, so the purpose of this study was to investigate the effect of L-Carnitine supplementation on inflammatory markers in the critically ill patient. Methods: This randomized, double-blind, placebo-controlled trial was performed on 50 critically ill patients. The subjects were randomly assigned to the placebo group (n=26) and L-carnitine group (n=24), the intervention (3000mg/day) was administered for 7 days. The levels ofinflammatory marker (CRP, IL-6, Procalctitonin) were measured. APACHE score, SOFA score, and 28-day mortality were calculated.Results: fifty critical ill patient’s completed the study. After L-Carnitine supplementation, the levels of inflammation marker were significantly reduced compared to the baseline (CRP P<0.02, IL-6 P=0.04, PCT P=0.03). In the placebo group the levels of inflammation marker were increased compared to the baseline. SOFA score were significantly reduced in carnation group compared to the placebo group (p=0.02) and APACHE score were significantly reduced in L-Carnitine group vs control group (p=0.01).Conclusions: this study showed that L-Carnitine supplementation may improve carnitine deficiency and decreased inflammation in critically ill patients.

کلیدواژه ها:

#VALUE!